Aim To report on the impact of COVID-19 on a brain damage unit. Methods We reviewed the records of all patients admitted to our brain damage unit. The study included all the significant clinical events from the first RT-PCR assay (April 8th, 2020) for SARS-CoV-2 to the day all patients tested negative (June 8th, 2020). Results Of the 20 patients (14 men) (age 57.7 ± 14.9; 2–71 months after brain damage; all with a Rankin scale > 4), 16 tested positive for SARS-CoV-2 and remained positive for a mean of 32.3 days (ranging from 26 to 61). One patient died from COVID-19, while 12 patients were asymptomatic and three suffered mild pneumonia without acute respiratory distress syndrome. All patients received prophylactic subcutaneous heparin. Intravenous methylprednisolone was prescribed for three patients with bilateral pneumonia with excellent results. Conclusions Most positive cases (93.7%) were not severe. The good outcome was most likely due to the use of phylactic anticoagulation therapy, the early use of methylprednisolone for pneumonia, and the previously reported immunosuppression amid patients with brain damage. This study hopes to encourage further study into brain damage immunity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.